Key result
Hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) demonstrate preclinical and early clinical potential for treating nonanemic diseases such as acute kidney injury, retinopathy, and cardiovascular conditions.
Why the study?
Because HIFs participate in diverse physiological and pathological processes, efforts have focused on extending the therapeutic potential of HIF-PHIs beyond chronic kidney disease anemia.
Do hypoxia inducible factors prolyl hydroxylase inhibitors (HIF-PHIs) provide therapeutic benefits in nonanemic diseases?
Do hypoxia inducible factors prolyl hydroxylase inhibitors (HIF-PHIs) provide therapeutic benefits in nonanemic diseases?
HIF-PHIs are effective for treating CKD anemia and show promising pleiotropic organ-protective effects in preclinical models, but their long-term cardiovascular and oncologic safety profiles require further clinical validation.
No takes yet. Share an insight, caveat, or question.
May expand HIF-PHI applications beyond anemia; leaves open efficacy confirmation in nonanemic cardiovascular trials.
Miao et al. (2022) conducted a review in Nonanemic Diseases. Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors (HIF-PHIs) was evaluated. Hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) demonstrate preclinical and early clinical potential for treating nonanemic diseases such as acute kidney injury, retinopathy, and cardiovascular conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: